2019

15/11/2019

Proteomics International raises $3m in heavily oversubscribed Placement

12/11/2019

CE Mark for predictive test for diabetic kidney disease

31/10/2019

Appendix 4C – September 2019 Quarterly Report

29/10/2019

Proteomics receives $1.1 million in R&D tax incentive

21/10/2019

Notice of Annual General Meeting/Proxy Form

21/10/2019

PIQ market update

17/09/2019

PromarkerD IVD successfully developed and validated

13/09/2019

PromarkerD launched in Spain

12/09/2019

PromarkerD test ready for launch in Europe

10/09/2019

PromarkerD latest results published in peer reviewed journal

30/08/2019

Annual Report to shareholders

30/08/2019

Preliminary Final Report

30/08/2019

Corporate Governance Statement and Appendix 4G

30/07/2019

Appendix 4C – June 2019 Quarterly Report

29/07/2019

PromarkerD secures TGA software approval & Indonesian patent

26/07/2019

Proteomics secures contracts for pharmacokinetic analysis

13/06/2019

PIQ investor presentation – 121 Tech Investment Hong Kong

07/06/2019

PromarkerD to feature at world’s largest diabetes conference

03/06/2019

Proteomics to showcase PromarkerD at BIO Convention

23/05/2019

Exercise of Options – Secondary Trading Notice & Appendix 3B

24/04/2019

Appendix 4C – March 2019 Quarterly Report

27/02/2019

Appendix 4D and Interim Financial Report

22/02/2019

US patent for identifying drugs for abnormal kidney function

30/01/2019

Appendix 4C – December 2018 Quarterly Report

24/01/2019

PromarkerD US market update

15/01/2019

Exercise of Options – Secondary Trading Notice & Appendix 3B

Subscribe
  • This field is for validation purposes and should be left unchanged.